| Literature DB >> 33570624 |
Eszter Doma1, Isabella Maria Mayer1, Tania Brandstoetter1, Barbara Maurer1, Reinhard Grausenburger1, Ingeborg Menzl1, Markus Zojer1, Andrea Hoelbl-Kovacic1, Leif Carlsson2, Gerwin Heller1,3, Karoline Kollmann1, Veronika Sexl1.
Abstract
Studies of molecular mechanisms of hematopoiesis and leukemogenesis are hampered by the unavailability of progenitor cell lines that accurately mimic the situation in vivo. We now report a robust method to generate and maintain LSK (Lin-, Sca-1+, c-Kit+) cells, which closely resemble MPP1 cells. HPCLSKs reconstitute hematopoiesis in lethally irradiated recipient mice over >8 months. Upon transformation with different oncogenes including BCR/ABL, FLT3-ITD, or MLL-AF9, their leukemic counterparts maintain stem cell properties in vitro and recapitulate leukemia formation in vivo. The method to generate HPCLSKs can be applied to transgenic mice, and we illustrate it for CDK6-deficient animals. Upon BCR/ABLp210 transformation, HPCLSKsCdk6-/- induce disease with a significantly enhanced latency and reduced incidence, showing the importance of CDK6 in leukemia formation. Studies of the CDK6 transcriptome in murine HPCLSK and human BCR/ABL+ cells have verified that certain pathways depend on CDK6 and have uncovered a novel CDK6-dependent signature, suggesting a role for CDK6 in leukemic progenitor cell homing. Loss of CDK6 may thus lead to a defect in homing. The HPCLSK system represents a unique tool for combined in vitro and in vivo studies and enables the production of large quantities of genetically modifiable hematopoietic or leukemic stem/progenitor cells.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33570624 PMCID: PMC7805318 DOI: 10.1182/bloodadvances.2020003022
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529